Department of General Surgery, the First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, PR China.
Mol Med Rep. 2012 Oct;6(4):779-82. doi: 10.3892/mmr.2012.981. Epub 2012 Jul 9.
To examine the pathological features and prognosis of different molecular subtypes of breast cancer, the clinical data of 892 breast cancer patients were retrospectively analyzed and divided into four subtypes according to hormone receptor expression in breast cancer tissue: Her-2 overexpression, luminal A, luminal B and basal-like subtypes. The pathological data and prognosis of these subtypes were compared. Of the 892 breast cancer patients, there were 46 cases (5.2%) with Her-2 overexpression-type, 698 cases (78.3%) with luminal A-type, 38 cases (4.3%) with luminal B-type and 110 patients (12.2%) with basal-like-type. Immunohistochemistry was used to identify the progesterone and estrogen receptors in the tumor tissues. The χ2 test was used to verify the measurement data. The Cox proportional hazard regression model was used for the univariate and multivariate analyses. Results showed there was no statistical difference for lymphatic metastasis among the various molecular subtypes of breast cancer (P>0.05). The distant metastatic rate of patients with Her-2-type breast cancer was significantly higher compared to patients with the other three subtypes (P<0.05). The difference in local recurrence among molecular subtypes was not significantly significant (P>0.05). Lymph node metastasis, age and different molecular subtypes were found to have an impact on patient overall survival (OS) and disease-free survival (DFS). Her-2 overexpression-type breast cancer patients had the lowest 9-year DFS and 7-year OS compared to the other subtypes (P<0.05). Thus, Her-2-type was associated with the worst prognosis. In conlusion, the molecular typing of breast cancer has important clinical value in prognosis estimation and is expected to affect breast cancer treatment approaches.
为了研究不同分子亚型乳腺癌的病理特征和预后，回顾性分析了 892 例乳腺癌患者的临床资料，根据乳腺癌组织中激素受体的表达将其分为 4 个亚型：Her-2 过表达型、Luminal A 型、Luminal B 型和基底样型。比较了这些亚型的病理数据和预后。892 例乳腺癌患者中，Her-2 过表达型 46 例（5.2%），Luminal A 型 698 例（78.3%），Luminal B 型 38 例（4.3%），基底样型 110 例（12.2%）。免疫组织化学法检测肿瘤组织中孕激素和雌激素受体。采用 χ2 检验验证计量资料。采用 Cox 比例风险回归模型进行单因素和多因素分析。结果显示，不同分子亚型乳腺癌的淋巴结转移率无统计学差异（P>0.05）。Her-2 型乳腺癌患者的远处转移率明显高于其他三型（P<0.05）。分子亚型之间局部复发率无显著差异（P>0.05）。淋巴结转移、年龄和不同的分子亚型均对患者的总生存（OS）和无病生存（DFS）有影响。与其他亚型相比，Her-2 过表达型乳腺癌患者 9 年 DFS 和 7 年 OS 最低（P<0.05）。因此，Her-2 型与最差的预后相关。结论：乳腺癌的分子分型对预后评估具有重要的临床价值，有望影响乳腺癌的治疗方法。
